We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene Showcases All-in-One Platform for Molecular Diagnostic Testing for Infectious Diseases

By LabMedica International staff writers
Posted on 25 Apr 2022
Image: All-in-One Platform performs molecular diagnostic tests for infectious diseases (Photo courtesy of Seegene)
Image: All-in-One Platform performs molecular diagnostic tests for infectious diseases (Photo courtesy of Seegene)

Seegene, Inc. (Seoul, Korea) showcased its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022).

ECCMID is the world’s premier clinical microbiology & infectious diseases event that brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program. During this event, Seegene showcased AIOS – its first fully automated MDx system. AIOS provides high-throughput real-time PCR workflow starting from nucleic acid extraction, then, real-time PCR, and finally result interpretation. AIOS is a fully automated syndromic MDx system designed in a modular concept while it compiles Seegene’s cutting-edge high multiplex real-time PCR technologies.

A noteworthy feature of AIOS is that its MDx system is composed of independent and detachable modules together with its proprietary SW architecture. Unlike others’ single-body system, AIOS is designed with an extraction/liquid handler and PCR instrument being integrated with an in-house developed robotic arm module. Hospitals and laboratories can either purchase the full package of ‘AIOS’ system or integrate their existing instruments on-site if they already have Seegene’s liquid handler and real-time PCR instrument.

Some of its other highlights include: ‘high-throughput automated syndromic MDx system’. It also adopts a variety of Seegene’s assays that are currently available on the market, which allows for symptom-based tests. And finally, it can identify the exact cause of a specific symptom with a single tube, which will enable both cost- and time- effective tests. The AIOS is ideal for small-to-medium sized hospitals due to its unique modular and assay features.

Related Links:
Seegene, Inc. 

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Automatic CLIA Analyzer
Shine i9000

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
INTEGRA BIOSCIENCES AG